Ascendis Pharma AS (NAS:ASND)
$ 151.26 -2.17 (-1.41%) Market Cap: 8.67 Bil Enterprise Value: 9.12 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Ascendis Pharma A/S Corporate Call Transcript

Nov 14, 2022 / 01:00PM GMT
Release Date Price: $110.26 (-16.45%)
Operator

Good day, and thank you for standing by. Welcome to Ascendis Pharma TransCon CNP ACcomplisH Trial Top Line Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to turn the conference over to your speaker today, Tim Lee, Senior Director of Investor Relations. Please go ahead.

Timothy J. Lee;S;Senior Director of IR
Ascendis Pharma A

/-

Thank you, operator, and thanks, everyone, for joining our Trial top line results conference call today. I'm Tim Lee, Senior Director, Investor Relations of Ascendis Pharma.

As a part of today's webcast, we have an accompanying slide deck that you can find on the Investor Relations section of our company website.

Joining me on the call today is Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Senior Vice President and Chief Financial Officer; Dr. Birgitte Volck, Senior Vice President, Head of Clinical Development and Medical, Endocrinology Rare Diseases; and Dr. Amy Su, Vice

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot